LYON, France--(BUSINESS WIRE)--Flamel Technologies (Nasdaq:FLML) today announced its financial results for the third quarter of 2011.
•Completion of new supply agreement with GlaxoSmithKline (NYSE: GSK) for the production of Coreg CR microparticles. •Completion of a license and development agreement with Eagle Pharmaceuticals for a Medusa-enabled subcutaneous formulation of tigecycline, an antibiotic currently indicated for the treatment of a variety of serious infections via intravenous administration.
•Completion of new supply agreement with GlaxoSmithKline (NYSE: GSK) for the production of Coreg CR microparticles. •Completion of a license and development agreement with Eagle Pharmaceuticals for a Medusa-enabled subcutaneous formulation of tigecycline, an antibiotic currently indicated for the treatment of a variety of serious infections via intravenous administration.
